How to Document AI and Automation Use for Inspections and Submissions How to Document AI and Automation Use for Inspections and Submissions As the pharmaceutical and biotechnology industries continue to evolve, the integration of artificial intelligence (AI), automation, and advanced analytics is becoming increasingly prevalent. For Regulatory Affairs (RA) professionals, navigating the complexities of these technologies while ensuring compliance with regulatory requirements is critical. This regulatory explainer manual provides a structured overview of the relevant regulations, guidelines, and expectations concerning AI and automation in pharma, with a particular focus on 21 CFR Part 11 compliance, EU Annex 11 requirements, and…

Using Robotics and RPA in PV, RA and Quality Operations Safely Using Robotics and RPA in PV, RA and Quality Operations Safely The integration of robotics and robotic process automation (RPA) into pharmacovigilance (PV), regulatory affairs (RA), and quality (QA) operations presents both opportunities and challenges. This article will explore the implications of integrating advanced digital systems within regulatory frameworks, focusing on ensuring compliance with 21 CFR Part 11, EU Annex 11, and related Good Automated Manufacturing Practice (GxP) guidelines. Regulatory Affairs Context The role of Regulatory Affairs is pivotal in guiding pharma and biotech companies in navigating the complex…

Real-World Data, Real-World Evidence and Advanced Analytics in Submissions Real-World Data, Real-World Evidence and Advanced Analytics in Submissions Context The integration of digital systems, advanced analytics, and artificial intelligence (AI) has transformed the pharmaceutical industry, especially in the realm of regulatory affairs. With the rise of real-world data (RWD) and real-world evidence (RWE), regulatory bodies increasingly expect the incorporation of these elements into submissions. Consequently, professionals in Regulatory Affairs (RA), Chemistry, Manufacturing and Controls (CMC), and Labelling teams within the US, UK, and EU need to understand the regulatory frameworks and guidelines that govern these practices. This article aims to…

Risk Assessments for AI Systems in GxP and Decision-Making Workflows Risk Assessments for AI Systems in GxP and Decision-Making Workflows The rapid evolution of artificial intelligence (AI) technologies in the pharmaceutical sector presents both opportunities and challenges, particularly regarding regulatory compliance. Understanding the regulatory frameworks governing AI systems is critical for Regulatory Affairs (RA) professionals, especially those involved in Good Practice (GxP) environments. This article aims to provide a comprehensive overview of risk assessments for AI systems within GxP contexts, ensuring alignment with regulatory expectations in the US, UK, and EU. Regulatory Context for AI Systems in GxP As pharmaceutical…

Building Cross-Functional AI Governance Committees with RA Involvement Building Cross-Functional AI Governance Committees with RA Involvement The integration of advanced technologies such as Artificial Intelligence (AI) and automation into the pharmaceutical sector is increasingly critical as companies strive to enhance efficiency, compliance, and innovation. In this regulatory explainer manual, we will outline the context of Regulatory Affairs (RA) within the framework of AI governance, the legal and regulatory basis for compliance concerning 21 CFR Part 11, EU Annex 11 requirements, and GxP digital systems and validation. We will describe how RA teams can actively participate in cross-functional AI governance committees…

Digital Twins and Predictive Models: Regulatory Opportunities and Risks Digital Twins and Predictive Models: Navigating Regulatory Opportunities and Risks Context The pharmaceutical industry is undergoing a digital transformation, enhancing clinical research, manufacturing processes, and product lifecycle management through the adoption of digital twins, predictive models, and advanced analytics. These cutting-edge technologies promise to optimize operations and improve patient outcomes. However, with these advancements come significant regulatory considerations, particularly with regard to compliance with established guidelines such as 21 CFR Part 11 in the U.S. and EU Annex 11 in the European Union. Legal/Regulatory Basis The integration of digital systems in…

Global Guidance Landscape on AI in Medicines Regulation (FDA, EMA, MHRA) Global Guidance Landscape on AI in Medicines Regulation (FDA, EMA, MHRA) Regulatory Affairs Context In the evolving landscape of pharmaceuticals, the integration of artificial intelligence (AI), automation, and advanced analytics is becoming increasingly prominent. Regulatory Affairs (RA) professionals must navigate a complex web of regulations and guidelines governing the development and approval of these technologies. Understanding the implications of AI in medicines is critical for ensuring compliance with regulations such as 21 CFR Part 11 in the US, EU Annex 11 requirements, and relevant Good Automated Manufacturing Practice (GxP)…

Training Teams to Use AI Tools Correctly Without Creating Compliance Gaps Training Teams to Use AI Tools Correctly Without Creating Compliance Gaps Context As the pharmaceutical industry continually evolves with emerging technologies, the application of Artificial Intelligence (AI), automation, and advanced analytics in drug development and regulatory compliance is on the rise. Regulatory Affairs (RA) professionals in the pharmaceutical sector must adeptly navigate 21 CFR Part 11 compliance, EU Annex 11 requirements, and Good Automated Manufacturing Practice (GxP) standards to ensure that the use of these tools does not inadvertently create compliance gaps. This article serves as a comprehensive regulatory…

KPIs and Metrics for Monitoring AI and Automation Performance and Risk KPIs and Metrics for Monitoring AI and Automation Performance and Risk In the rapidly evolving landscape of the pharmaceutical industry, the integration of artificial intelligence (AI) and automation into regulatory frameworks presents both opportunities and challenges. Regulatory Affairs (RA) professionals must ensure compliance with various guidelines, such as 21 CFR Part 11 in the US, EU Annex 11 requirements, and other Good Automated Manufacturing Practice (GxP) regulations. Context The pharmaceutical sector increasingly relies on digital systems and advanced analytics to streamline processes, enhance productivity, and maintain quality control. However,…

Future Outlook: How AI May Reshape Regulatory Affairs and Quality Systems Future Outlook: How AI May Reshape Regulatory Affairs and Quality Systems The integration of Artificial Intelligence (AI) and automation into regulatory affairs is poised to transform pharmaceutical and biotech industries significantly. This article aims to provide a structured examination of the current regulatory landscape pertaining to AI and digital systems, specifically through the lens of 21 CFR Part 11 compliance, EU Annex 11 requirements, and the broader context of Good Practice (GxP) in validation. As regulatory professionals, understanding how these evolving technologies intersect with regulatory guidelines is essential for…